Compare Unity Software Inc (U) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Unity Software Inc vs Viatris Inc — how do they compare? Unity Software Inc trades at $42.65 (market cap $18.81B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Unity Software Inc and Viatris Inc are close in size by market cap, and Viatris Inc pays a 2.89% dividend while Unity Software Inc pays none. Which is the better fit depends on your goals.
| U | VTRS | |
|---|---|---|
Market Cap | $18.81B | $19.09B |
Sector | Technology | Health |
52-Week High | $49.47 | $17.86 |
52-Week Low | $17.13 | $9.49 |
Enterprise Value | $18.70B | $31.21B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Unity Software (U) trades at $42.75, up 2.62% with bullish technical signals and strong analyst support. The company shows improving fundamentals with revenue stabilizing around $1.8B and narrowing losses, though still reporting negative net income. Recent Q2 2026 earnings beat expectations, while institutional activity shows mixed positioning with some major funds increasing stakes. Technical indicators suggest bullish momentum with support at $41 and resistance at $44.
The outlook remains cautiously optimistic with 81% analyst buy ratings and $47.45 price target, representing 11% upside. Key opportunities include Vector platform growth and margin expansion, while risks center on sustained profitability challenges and competitive pressures in the gaming/ad tech space. Execution on strategic initiatives will be critical for stock performance.
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
